News Center-CHIGENOVO Co., Ltd. Drug development|Ophthalmic diseases

NEWS CENTER

2024-07

2024

ZVS203e injection obtained IND approvals from China NMPA ZVS101e injection received Breakthrough Therapy designation from China NMPA Initiated ZVS101e phase III clinical trial

2024-07-01

2024-05

Usher syndrome

2024-05-24

2024-05

Familial exudative vitreoretinopathy

2024-05-24

2024-05

Diseases of lens

2024-05-24

2024-05

Corneal Dystrophy

2024-05-24

2024-05

Genetic testing for macular diseases

2024-05-24

2024-05

Optic nerve atrophy

2024-05-24

2024-05

Genetic screening for early onset myopia/amblyopia

2024-05-23

2024-05

Retinitis pigmentosa

2024-05-23

2024-05

Risk assessment for high myopia

2024-05-23

< 1 2 3 4 5 >

CHIGENOVO Co., Ltd. is an ophthalmic gene therapy company, a national high-tech enterprise focusing on genetic diagnosis of genetic eye diseases and the development of gene therapy drugs. It is committed to providing "one-stop" services for patients with genetic eye diseases.

Telephone:400-6006223 010-82071936
Website:en.chinagene.cc
Address: Floor 4, Area D, Building 1, No.27 Life Garden Road, Zhongguancun Life Science Park, Changping District, Beijing

WeChat subscription account

Business License

NEWS CENTER

HUATAO GROUP